Halil Genc

Halil Genc

Auto-generated profile, based on publicly available information

Halil Genc

Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
TDTeoman Dogru
Teoman Dogru
Alper SonmezAlper Sonmez
Alper Sonmez
ITIlker Tasci
Ilker Tasci
EBErgun Bozoglu
Ergun Bozoglu
MYMahmut Ilker Yilmaz
Mahmut Ilker Yilmaz
SBSezin Bingol
Sezin Bingol

7 June 2012 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
TDTeoman Dogru
Teoman Dogru
HGHalil Genc
Halil Genc
STSerkan Tapan
Serkan Tapan
FAFatih Aslan
Fatih Aslan
CECemal Nuri Erci̇n
Cemal Nuri Erci̇n
Alper SonmezAlper Sonmez
Alper Sonmez

26 May 2010 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
PDF file
Alper SonmezAlper Sonmez
Alper Sonmez
GCGurkan Celebi
Gurkan Celebi
GEGokhan Erdem
Gokhan Erdem
STSerkan Tapan
Serkan Tapan
HGHalil Genc
Halil Genc
MKMustafa Kutlu
Mustafa Kutlu
Both apelin and asymetric dymethyl arginine (ADMA) regulate blood pressures. Low apelin and high ADMA levels have been reported in several cardiometabolic disorders. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them. We investigated a group of newly diagnosed and untreated 30 young hypertensive men and 30 healthy controls. Apelin levels were significantly lower and the ADMA levels were significantly higher in the patients (p = 0.04 for both). Both ADMA and apelin were related to the systolic blood pressures (SBP) (beta = −0.393, p = 0.003; beta = 0.285, p = 0.03, respectively). Future studies are necessary in order to clearly define the role of ADMA and apelin in the pathogenesis of essential hypertension.

1 April 2014 in Clinical Biochemistry
Verified
Journal Article
Closed access
ESErdim Sertoglu
Erdim Sertoglu
CECemal Nuri Erci̇n
Cemal Nuri Erci̇n
GCGurkan Celebi
Gurkan Celebi
HGHasan Gurel
Hasan Gurel
HKHuseyin Kayadibi
Huseyin Kayadibi
TDTeoman Dogru
Teoman Dogru

1 July 2015 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
Alper SonmezAlper Sonmez
Alper Sonmez
DNDragana Nikolic
Dragana Nikolic
TDTeoman Dogru
Teoman Dogru
CECemal Nuri Erci̇n
Cemal Nuri Erci̇n
HGHalil Genc
Halil Genc
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO

1 July 2013 in Annals of Hepatology
Verified
Journal Article
Open access
HGHalil Genc
Halil Genc
TDTeoman Dogru
Teoman Dogru
MKMuammer Kara
Muammer Kara
STSerkan Tapan
Serkan Tapan
CECemal Nuri Erci̇n
Cemal Nuri Erci̇n
SBSait Bagci
Sait Bagci
Visfatin is a proinflammatory and insulin-mimetic adipokine contributing to whole body glucose and lipid metabolism. Studies to date are conflicting regarding the relationship between visfatin and non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the relationship of circulating visfatin with NAFLD. The study included 114 NAFLD patients and 60 healthy non-diabetic controls. Plasma visfatin, adiponectin, tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels were measured by ELISA. High sensitive C-reactive protein (hsCRP) levels were measured by immunoturbidimetric fixed rate method. Insulin sensitivity determined by homeostasis model assessment (HOMA-IR) index. TNF-α, IL-6 and hsCRP levels were higher and, Adiponectin levels were lower in NAFLD group when compared to healthy controls (p < 0.001, for all). However, no difference was found regarding to visfatin levels between two groups. Different histologic subgroups of NAFLD had a significantly higher TNF-α, IL-6 and hsCRP, and lower adiponectin levels than those with controls (p < 0.001, for all). On the other hand, no statistically significant difference was found regarding to visfatin levels among different histologic groups. Visfatin was found to be negatively correlated with TNF-α (r = -0.236, p = 0.011) in NAFLD group. However, no association was found between visfatin and histological findings. Our findings show that plasma visfatin levels are not altered in the early stages of NAFLD. However, it is inversely associated with TNF-α. These findings suggest a role for visfatin in protection against liver injury in this widespread disease.